Patents by Inventor Catherine M. BOLLARD

Catherine M. BOLLARD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof
    Patent number: 11931465
    Abstract: Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 19, 2024
    Assignee: Children's National Medical Center
    Inventors: Rohan Fernandes, Raymond W. Sze, Conrad Russell Y. Cruz, Anthony D. Sandler, Catherine M. Bollard, Elizabeth E. Sweeney, Juliana Cano-Mejia, Rachel Burga, Matthieu F. Dumont
  • Generating HPV antigen-specific cells from a naive T cell population
    Patent number: 11649437
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: May 16, 2023
    Assignee: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Catherine M. Bollard, Conrad Russell Cruz, Patrick J. Hanley, Michael Keller
  • GENERATING HPV ANTIGEN-SPECIFIC CELLS FROM A NAIVE T CELL POPULATION
    Publication number: 20210163892
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Application
    Filed: January 19, 2021
    Publication date: June 3, 2021
    Applicant: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Catherine M. BOLLARD, Conrad Russell CRUZ, Patrick J. HANLEY
  • GENERATING HPV ANTIGEN-SPECIFIC CELLS FROM A NAIVE T CELL POPULATION
    Publication number: 20210155900
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 27, 2021
    Applicant: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Catherine M. BOLLARD, Conrad Russell CRUZ, Patrick J. HANLEY
  • Generating HPV antigen-specific cells from a naive T cell population
    Patent number: 10934525
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 2, 2021
    Assignee: Children's National Medical Center
    Inventors: Catherine M. Bollard, Conrad Russell Cruz, Patrick J. Hanley
  • FUNCTIONALIZED PRUSSIAN BLUE NANOPARTICLES, COMBINATION PRUSSIAN BLUE NANOPARTICLE-BASED NANO-IMMUNOTHERAPY AND APPLICATIONS THEREOF
    Publication number: 20200163899
    Abstract: Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.
    Type: Application
    Filed: March 8, 2017
    Publication date: May 28, 2020
    Applicant: Children's National Medical Center
    Inventors: Rohan FERNANDES, Raymond W. SZE, Conrad Russell Y. CRUZ, Anthony D. SANDLER, Catherine M. BOLLARD, Elizabeth E. SWEENEY, Juliana CANO-MEJIA, Rachel BURGA, Mathieu F. DUMONT
  • GENERATING HPV ANTIGEN-SPECIFIC CELLS FROM A NAIVE T CELL POPULATION
    Publication number: 20180312807
    Abstract: Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.
    Type: Application
    Filed: October 31, 2016
    Publication date: November 1, 2018
    Applicant: Children's National Medical Center
    Inventors: Catherine M. BOLLARD, Conrad Russell CRUZ, Patrick J. HANLEY
  • Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
    Patent number: 9885021
    Abstract: Compositions for T cell-based immunotherapy of HIV, HIV-associated malignancies, HIV-associated viral infections, or other HIV-related complications. Modified T cells that are resistant to invasion or infection with HIV, such as T-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (“MOGS”). Methods for producing such compositions by expanding HIV-specific T cells from different sources to recognize multiple HIV antigens.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 6, 2018
    Assignee: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Catherine M. Bollard, Conrad Russell Y. Cruz, Sharon Lam
  • GENERATION OF BROADLY-SPECIFIC, VIRUS-IMMUNE CELLS TARGETING MULTIPLE HIV ANTIGENS FOR PREVENTIVE AND THERAPEUTIC USE
    Publication number: 20150359876
    Abstract: Compositions for T cell-based immunotherapy of HIV, HIV-associated malignancies, HIV-associated viral infections, or other HIV-related complications. Modified T cells that are resistant to invasion or infection with HIV, such as T-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (“MOGS”). Methods for producing such compositions by expanding HIV-specific T cells from different sources to recognize multiple HIV antigens.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Applicant: Children's National Medical Center
    Inventors: Catherine M. BOLLARD, Conrad Russell Y. Cruz, Sharon Lam